Sustained-release drug carrier composition
The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
1. A medical device comprising: a substrate and a biocompatible coating deposited on at least a fraction of said substrate, wherein said biocompatible coating comprises a matrix composition having an ordered alternating multilayer structure, said matrix composition comprising:
a. a biodegradable polymer in non-covalent association with a first lipid having a polar group, wherein said first lipid comprises a sterol;
b. a second lipid comprising at least one phosphatidylcholine having hydrocarbon chains of at least 14 carbons;
c. at least one pharmaceutical active agent;
wherein the matrix composition is lipid saturated and said ordered alternating multilayer structure comprises said biodegradable polymer and said lipids, wherein each biodegradable polymer layer is separated by a layer of lipids; wherein the weight ratio of total lipids to said biodegradable polymer is between 1.5:1 and 9:1 inclusive; and wherein the release time of 90% of the active ingredient from the matrix composition is between 1 week and 6 months, wherein at least 50% of said pharmaceutical active agent is released from the composition at zero-order kinetics when said matrix is maintained in an aqueous environment.
2. The device of claim 1 wherein the biodegradable polymer is a biodegradable polyester selected from the group consisting of PLA (polylactic acid), PGA (poly glycolic acid) and PLGA (Poly (lactic co glycolic acid).
3. The device composition of claim 1 wherein the pharmaceutical active agent is selected from an antibiotic, an antifungal, a non-steroidal anti-inflammatory drug, a steroid, an anti-cancer agent, an osteogenic factor and a bone resorption inhibitor.
4. The device of claim 1 , wherein said matrix composition is homogeneous.
5. The device of claim 1 , wherein the matrix composition further comprises at least one of (a) a tocopherol; (b) a compound selected from the group consisting of sphingolipid, a free fatty acid having 14 or more carbon atom, an additional phospholipid selected from the group consisting of a phosphatidylserine, a phosphatidylglycerol, and a phosphatidylinositol; and (c) a targeting moiety capable of interacting with a target molecule selected from the group consisting of a collagen molecule, a fibrin molecule and a heparin.
6. A method of administering a pharmaceutically active agent to a subject, said method comprising the step of implanting in said subject the medical device of claim 1 , wherein the pharmaceutically active agent is selected from the group consisting of an antibiotic, an antifungal, a non-steroidal anti-inflammatory drug, a steroid, an anti-cancer agent, an osteogenic factor and a bone resorption inhibitor.
7. The device of claim 6 , wherein said sterol is cholesterol.
8. The device of claim 7 , wherein said cholesterol is present in an amount of 5-50 mole percent of the total lipid content of said matrix composition.
9. The medical device of claim 1 , wherein said substrate is selected from orthopedic nails, orthopedic screws, orthopedic staples, orthopedic wires, orthopedic pins, metal or polymeric implants, bone filler particles, collagen and non-collagen membranes, suture materials, orthopedic cements and sponges.
10. A method of treating periodontitis in a subject in need thereof, said method comprising the step of implanting in the periodontium of said subject a medical device of claim 1 wherein the pharmaceutically active agent is an antibiotic.
11. The method of claim 10 , wherein the matrix composition further comprises at least one of an osteogenic factor and a bone resorption inhibitor.
12. A method of stimulating bone augmentation in a subject in need thereof, said method comprising the step of implanting in said subject the medical device of claim 1 , wherein the pharmaceutically active agent is selected from an osteogenic factor and a bone resorption inhibitor.
13. The device of claim 2 , wherein the pharmaceutical active agent is an antibiotic.
14. The device of claim 13 , wherein the sterol is cholesterol.
15. The device of claim 14 , wherein the phosphatidyl choline is selected from the group consisting of DSPC, DPPC, DOPC, and any combination thereof.
16. The device of claim 15 , wherein the substrate is a bone filler particle.
17. The device of claim 16 wherein the antibiotic is doxycycline or doxycycline hyclate.
18. The device of claim 17 wherein the phosphatidyl choline comprises a combination of DPPC and DSPC.
19. The device of claim 18 wherein the biodegradable polyester is PLGA.
20. The device of claim 19 wherein the bone filler particle is a tri calcium phosphate granule.